Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAT2 | Q10469 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24157277 | 1.00 | MGAT2 (0.34) | MGAT2BRD4CREBBPMAPTKDM4E | |
| SCHEMBL24157241 | 0.84 | MGAT2 (0.34) | MGAT2BRD4CREBBPMAPTKDM4E | |
| SCHEMBL30212699 | 0.84 | MGAT2 (0.34) | MGAT2BRD4CREBBPMAPTKDM4E | |
| SCHEMBL24157270 | 0.82 | PGR (0.34) | MGAT2BRD4CREBBPMAPTKDM4E | |
| SCHEMBL24156584 | 0.80 | BRPF1 (0.46) | BRD4CREBBP | |
| SCHEMBL30212561 | 0.80 | BRPF1 (0.46) | BRD4CREBBP | |
| SCHEMBL24156604 | 0.77 | GAA (0.38) | KDM4ETHRB | |
| SCHEMBL30212609 | 0.75 | GAA (0.30) | THRB | |
| SCHEMBL24156578 | 0.75 | GAA (0.30) | THRB | |
| SCHEMBL24157371 | 0.74 | GAA (0.32) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059929-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122036687-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036686-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010903-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4452256-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | Astrazeneca AB (SE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118496203-A | Quinoxaline compound and medical application thereof | 苏州隆博泰药业有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118317793-A | Methods for treating brain tumors and neuroblastomas | 阿斯利康(瑞典)有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4172152-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | Astrazeneca AB (SE) | 2023-05-03 | — | — | EP | disclosed |
| CN-115768760-A | Quinoxaline derivatives as anti-cancer agents | 阿斯利康(瑞典)有限公司 | 2023-03-07 | — | — | CN | disclosed |